lamivudine has been researched along with Liver Neoplasms in 175 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (5.14) | 18.2507 |
| 2000's | 77 (44.00) | 29.6817 |
| 2010's | 83 (47.43) | 24.3611 |
| 2020's | 6 (3.43) | 2.80 |
| Authors | Studies |
|---|---|
| Funk, A; Gaertner, K; Krahn, I; Lin, L; Matthes, E; Sirma, H; von Janta-Lipinski, M; Will, H | 1 |
| Ayres, A; Bartholomeusz, A; Kuiper, M; Locarnini, S; Shaw, T; Warner, N; Yuen, L | 1 |
| Chen, W; Gu, X; Guan, M; Huang, X; Li, X; Qiu, J; Zhang, Y; Zhao, Y; Zhou, Q; Zou, Y | 1 |
| Arai, K; Hayakawa, N; Honda, M; Horii, R; Kagaya, T; Kaneko, S; Kawaguchi, K; Komura, T; Mizukoshi, E; Nio, K; Nishikawa, M; Orita, N; Sakai, Y; Shimakami, T; Shimode, T; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Li, DM; Li, J; Sun, CH; Sun, FY; Yu, H; Zhang, J | 1 |
| Ahn, SH; Baek, YH; Chang, Y; Choe, WH; Jang, JW; Jang, JY; Kim, GA; Kim, HY; Kim, JH; Kim, M; Kim, MA; Kim, SG; Kim, SU; Kim, YJ; Kim, YS; Koh, M; Kwon, JH; Lee, HA; Lee, HW; Lee, JH; Lee, SW; Lee, YS; Lim, YS; Park, Y; Seo, YS; Shim, JJ; Sinn, DH; Yang, H; Yim, HJ; Yoon, JH; Zoulim, F | 1 |
| Heller, T; Hercun, J; Koh, C | 1 |
| Chien, RN; Chu, YD; Huang, YH; Ke, PY; Liang, KH; Lin, CL; Lin, KH; Lin, YH; Yeh, CT | 1 |
| Chen, G; Chen, S; Chen, Y; Cheng, J; Ding, H; Jia, J; Jiang, W; Kong, Y; Ma, A; Ma, H; Meng, T; Ou, X; Piao, H; Shi, Y; Sun, Y; Wang, B; Wu, X; Xie, W; Xu, M; Xu, X; Xu, Y; You, H; Zhou, J | 1 |
| Ahn, SH; Chon, YE; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Myoung, SM; Park, JY | 1 |
| He, L; Jiang, Y; Liu, X; Wang, X; Yang, Z; Zhang, S; Zhao, Y | 1 |
| Bair, MJ; Chen, CJ; Chen, MJ; Chu, CH; Lin, CC; Lin, ZY; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Ahn, SH; Bae, SH; Cheong, JY; Han, KH; Jang, BK; Jeong, SW; Kim, BI; Kim, DJ; Kim, JK; Kim, MY; Kim, SG; Kim, TY; Kwon, JH; Kwon, SY; Lee, HW; Lee, JW; Myoung, S; Park, JY; Seo, YS; Tak, WY; Yim, HJ; Yoon, KT | 1 |
| Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B | 1 |
| Akita, T; Kumada, T; Kurisu, A; Miyake, N; Ohisa, M; Tada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| David, E; Marengo, A; Marzano, A; Rizzetto, M | 1 |
| Jiang, B; Li, L; Li, ZF; Song, SB; Xiu, DR; Yuan, CH; Zhang, TL | 1 |
| Hu, RH; Lee, CY; Lee, PH; Tsai, MK; Yang, YW | 1 |
| Fu, LY; Xu, CF | 1 |
| Gao, YJ; Jin, B; Li, HW; Liu, ZW; Ma, XM; Meng, FP; Su, HB; Zhang, M; Zhao, JM | 1 |
| Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH | 1 |
| An, J; Chung, YH; Kim, GA; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Ahn, SH; Hahn, KY; Han, KH; Kim, BK; Kim, DY; Kim, HC; Kim, JK; Kim, SU; Park, JY; Park, YH; Shin, SH | 1 |
| Deng, YR; Jin, QL; Lian, ZX; Matsuzaki, K; Moritoki, Y; Murata, M; Niu, JQ; Tsuneyama, K; Yamaguchi, T; Yoshida, K | 1 |
| Calvaruso, V; Craxì, A | 1 |
| Colombo, M; Della Corte, C; Triolo, M | 1 |
| Chanson, P; Pariente, A | 1 |
| Han, S; Heo, NY; Lee, HC; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Cho, HC; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sohn, W; Yoo, BC | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Choe, BH; Choe, HJ | 1 |
| Li, LQ; Ma, L; Zhong, JH | 1 |
| Jang, JY; Kim, BH; Kim, JW; Lee, CK; Shim, JJ | 1 |
| Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S | 1 |
| Chen, Y; Ge, N; Huang, P; Tang, W; Tian, H; Xia, J; Xu, X; Yang, B | 1 |
| Lin, GN; Liu, DY; Peng, JW; Xia, ZJ; Xiao, JJ | 1 |
| Berg, T; van Bömmel, F | 1 |
| Chouta, A; Dalekos, GN; Drakoulis, C; Gogos, C; Hatzis, G; Ilias, A; Karamanolis, D; Ketikoglou, I; Manesis, E; Manolakopoulos, S; Mela, M; Mimidis, K; Nikolopoulou, G; Papatheodoridis, GV; Raptopoulou-Gigi, M; Touloumi, G; Vafiadis-Zouboulis, I | 1 |
| Cheng, X; Dong, X; Hu, Q; Sun, P; Zheng, Q | 1 |
| Alcantara, L; Burak, KW; Coffin, CS; Klein, P; Myers, RP; Pang, JX; Rezaeeaval, M | 1 |
| Chen, J; Chen, ZH; Dong, M; Li, X; Lin, Q; Lin, ZX; Ma, XK; Ruan, DY; Wang, TT; Wei, L; Wen, JY; Wu, DH; Wu, XY; Xing, YF; Zhong, X | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| Chen, J; Ke, Y; Li, LQ; Ma, L; Xiao, HM; You, XM; Zhong, JH; Zhu, SL | 1 |
| Boettler, T; Thimme, R | 1 |
| Demirhan, YE; Gultekin, G; Isal, B; Khodor, H; Ozaras, R; Unal, UK; Yetim, N | 1 |
| Amani, A; Niederau, C; Thiel, A | 1 |
| Kowdley, K; Sundaram, V | 1 |
| Hiramatsu, N; Takehara, T; Yamada, R | 1 |
| Fu, WD; He, LX; Jiang, JN; Li, SH; Liang, P; Liu, ZH; Lu, AL; Mo, YY; Su, MH; Wang, BJ; Wu, XL; Xie, R; Zhong, SH | 1 |
| Fujioka, S; Ikeda, F; Kariyama, K; Kobashi, H; Miyatake, H; Morimoto, Y; Moriya, A; Okamoto, R; Seno, T; Takaguchi, K; Takaki, A; Takayama, H; Toshimori, J; Wada, N; Yabushita, K; Yamamoto, K; Yasunaka, T | 1 |
| Anzai, K; Arase, Y; Hirose, S; Kagawa, T; Mine, T; Nagata, N; Shiraishi, K; Tsuruya, K | 1 |
| Chan, SH; Chang, TT; Cheng, PN; Huang, W; Lin, YJ; Su, IJ; Tsai, HW; Wu, HC; Wu, IC; Yen, CJ | 1 |
| Ahn, H; An, H; Choe, WH; Jung, YK; Kim, JH; Kim, SG; Kim, SU; Kim, TY; Kim, YS; Lee, JH; Seo, YS; Suh, SJ; Suk, KT; Um, SH; Yim, HJ; Yim, SY | 1 |
| Choi, MS; Gwak, GY; Kim, H; Kim, JH; Kim, K; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH | 1 |
| Hiraoka, A; Kumada, T; Tada, T; Tanaka, J; Toyoda, H; Tsuji, K | 1 |
| Ahn, SH; Baatarkhuu, O; Han, KH; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Kim, YJ; Park, JW; Park, JY; Song, KJ | 1 |
| Auh, S; Ghany, MG; Hoofnagle, JH; Koh, C; Lau, DT; Lingala, S | 1 |
| Chmura, A; Cieciura, T; Jonas, M; Małkowski, P; Wasiak, D; Łągiewska, B | 1 |
| Kim, HY | 1 |
| Asano, M; Dohi, T; Enomoto, N; Gatanaga, H; Honda, M; Inoue, T; Kaneko, S; Kawamura, YI; Matsumoto, A; Mizokami, M; Murata, K; Nishida, N; Oka, S; Sakamoto, M; Shirasaki, T; Shuno, Y; Sugiyama, M; Tanaka, E; Yano, H | 1 |
| Kasai, K; Kuroda, H; Suzuki, K | 1 |
| Lee, HS | 1 |
| Lai, MW; Yeh, CT | 1 |
| Chien, RN; Liaw, YF | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 2 |
| Locarnini, S; Warner, N | 1 |
| Chang, MH; Hsu, CW; Huang, SF; Lai, MW; Liaw, YF; Yeh, CT | 1 |
| Buffet, C | 1 |
| Sherman, M | 1 |
| Kao, JH; Lim, SG; Mohammed, R; Yuen, MF | 1 |
| Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E | 1 |
| Lo, GH | 1 |
| Eun, JR; Kim, TN; Lee, HJ; Lee, KS | 1 |
| Lampertico, P; Lok, A; Manolakopoulos, S; Papatheodoridis, GV | 1 |
| Liaw, YF | 1 |
| Colombo, M | 1 |
| Pár, A | 1 |
| Bella, MR; Casas Rodrigo, M; Dalmau Obrador, B; Gil Prades, M; Miquel Planas, M; Puig Domingo, J; Sanchez Delgado, J; Vergara Gómez, M | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Arisawa, T; Hayashi, R; Nomura, T; Sato, K; Shiroeda, H; Tsutsumi, M; Yamada, M | 1 |
| Marcellin, P | 1 |
| Gogos, C; Ketikoglou, I; Manesis, EK; Manolakopoulos, S; Mimidis, K; Papatheodoridis, GV; Raptopoulou-Gigi, M; Touloumi, G; Vafiadis-Zoumbouli, I; Vasiliadis, T; Vourli, G | 1 |
| Brown, A; Thursz, M | 1 |
| Cho, YK; Song, BC | 1 |
| Chan, AC; Chan, SC; Chok, KS; Fan, ST; Lo, CM; Poon, RT; Yuen, WK | 1 |
| Chen, T; Chen, TC; Chen, YC; Hsu, CW; Lai, MW; Liang, KH; Yeh, CT | 1 |
| Ebinuma, H; Saito, H | 1 |
| Chien, RN | 1 |
| Chow, PY; Lee, KK; Lee, VW; Li, H; Wu, DB | 1 |
| Li, le Q; Wu, LC; Zhong, JH | 1 |
| Wong, GL | 1 |
| Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hiramatsu, N; Hosui, A; Iio, S; Imai, Y; Inui, Y; Ishida, H; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Katayama, K; Kiso, S; Kurokawa, M; Mita, E; Miyagi, T; Miyazaki, M; Mochizuki, K; Oshita, M; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H | 1 |
| Fujimori, M; Kumada, T; Sone, Y; Tada, T; Toyoda, H | 1 |
| Ahn, SH; Baatarkhuu, O; Chon, CY; Han, KH; Kim, DY; Kim, SU; Park, JY; Shin, HS | 1 |
| Chun, HJ; Jeen, YT; Jung, JY; Keum, B; Kim, CD; Kim, CH; Kim, JD; Kim, YS; Lee, HS; Ryu, HS; Seo, YS; Um, SH; Yim, HJ | 1 |
| Guyatt, G; Heels-Ansdell, D; Sun, X; Walter, SD | 1 |
| Anai, H; Honda, K; Maehara, S; Moriuchi, A; Muro, T; Seike, M; Tahara, K | 1 |
| Andou, Y; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Niinomi, T; Tada, T; Tanaka, J; Tanikawa, M; Toyoda, H; Yamamoto, K; Yasuda, S | 1 |
| Bae, SH; Choi, JY; Jang, JW; Kwon, JH; Park, CH; Yoo, SH; Yoon, SK | 1 |
| Cheng, H; Gong, W; Jiang, Y; Li, D; Liang, P; Zhang, J | 1 |
| Chen, X; Lu, M; Shi, H; Wang, Y; Wu, C; Xu, Y | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Fu, SY; Huang, G; Lau, WY; Pan, ZY; Shen, F; Wu, MC; Yang, Y; Zhou, WP | 1 |
| Alberti, A; Brunetto, MR; Colombo, M; Craxì, A | 1 |
| Davis, GL; Keeffe, EB | 1 |
| Furman, P; Martin, P; Pichoud, C; Seignères, B; Trépo, C; Zoulim, F | 1 |
| Bowden, S; Chen, RY; Colledge, D; Delaney, WE; Desmond, P; Edwards, R; Isom, H; Locarnini, SA; Shaw, T | 1 |
| Fisher, DA; Huffam, SE | 1 |
| Chan, FK; Chan, HL; Chui, AK; Lau, WY; Rao, AR; Wong, J | 1 |
| Fontana, RJ | 1 |
| Chen, M; Deng, W; Li, X; Ruan, L; Wang, Y; Zhou, G; Zhou, S; Zhou, Z | 1 |
| Färkkilä, M | 1 |
| Hidaka, S; Horiike, N; Iuchi, H; Konishi, I; Michitaka, K; Miyake, T; Nakanishi, S; Onji, M; Yoshino, I | 1 |
| Kirchner, JT; Lin, KW | 1 |
| Ganem, D; Prince, AM | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| Chan, HL; Chan, JY; Cheng, AS; Go, MY; Leung, WK; Liew, CT; Sung, JJ; To, KF | 1 |
| Abate, ML; Barbon, V; Fadda, M; Gaia, S; Lagget, M; Marzano, A; Niro, G; Olivero, A; Paganin, S; Rizzetto, M; Smedile, A | 1 |
| Almasio, PL; Andreone, P; Craxì, A; Di Marco, V; Lampertico, P; Marzano, A; Rizzetto, M; Santantonio, T | 1 |
| Fujisawa, T; Inui, A; Komatsu, H; Sogo, T | 1 |
| Ikeda, K | 1 |
| Chow, WC; Dixon, JS; Farrell, G; Gray, DF; Keene, ON; Lee, CZ; Liaw, YF; Sabbat, J; Shue, K; Sung, JJ; Tanwandee, T; Tao, QM; Yuen, H | 1 |
| Wands, JR | 1 |
| Akiyoshi, J; Itano, S; Koga, H; Kumashiro, R; Kurogi, J; Matsugaki, S; Nagamatsu, H; Nagaoka, S; Sata, M; Tajiri, N; Torimura, T; Yamasaki, S | 1 |
| Liu, Q; Tang, CW; Wang, CH; Xie, Y | 1 |
| Hiraoka, A; Hirooka, M; Horiike, N; Iuchi, H; Kubo, Y; Kumagi, T; Kurose, K; Michitaka, K; Miyaoka, H; Ohmoto, M; Okada, S; Onji, M; Uehara, T; Yamamoto, K; Yamashita, Y | 1 |
| Colombo, M; Donato, MF | 1 |
| Chen, H; Cheng, SQ; Cong, WM; Shen, F; Wang, PJ; Wu, MC; Yang, JH; Zhao, YX | 1 |
| Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D | 1 |
| Blake, MA; Blaszkowsky, LS; Chung, RT; Lauwers, GY; Tanabe, KK | 1 |
| Tang, CW; Wang, CH; Xie, Y | 1 |
| Gao, DC; Jia, JD; Liu, J; Sun, MC; Wang, BE; Wang, Y; Wu, GC; Wu, P; Zhang, D; Zhang, ZT | 1 |
| Chen, G; He, X; Huang, J; Zhu, X | 1 |
| Cheng, J; Guo, H; Guo, Y; Li, Z; Ma, S; Tao, J; Wang, F; Wang, W; Wang, Y; Xie, H; Yang, W; Zhang, L; Zhao, X; Zhou, Y | 1 |
| Araki, Y; Fujio, K; Fujioka, S; Hashimoto, K; Iwasaki, Y; Kaneyoshi, T; Kobashi, H; Nishida, T; Piao, CY; Sakaguchi, K; Senoh, T; Shiratori, Y; Terada, R | 1 |
| Chen, DS; Kao, JH; Liu, CJ | 1 |
| Kowdley, KV; Lim, LY | 1 |
| Bae, SH; Chang, UI; Cho, SH; Choi, JY; Han, JY; Jang, JW; Kim, CW; Lee, YS; Yoon, SK | 1 |
| Brunelle, MN; Carrouée-Durantel, S; Durantel, D; Jacquard, AC; Pichoud, C; Trepo, C; Zoulim, F | 1 |
| Gładysz, A; Knysz, B; Rzeszutko, M; Zalewska, M | 1 |
| Buster, EH; Janssen, HL | 1 |
| Schiff, ER | 1 |
| Arici, C; Castagna, A; Cozzi-Lepri, A; Dabis, F; De Luca, A; Garrido, M; Gervais, A; Gill, J; Ledergerber, B; Lundgren, JD; Milazzo, L; Moller, NF; Monforte, Ad; Mussini, C; Ourishi, N; Paraninfo, G; Puoti, M; Raffi, F; Rickenbach, M; Rockstroh, J; Suarez-Lozano, I; Winnock, M | 1 |
| Bara, C; Böker, KH; Deterding, K; Haverich, A; Manns, MP; Meyer, S; Pethig, K; Potthoff, A; Tillmann, HL; Wedemeyer, H | 1 |
| Cho, JY; Joh, JW; Kim, SI; Kwon, CH; Lee, KU; Lee, KW; Lee, SK; Suh, KS; Yi, NJ | 1 |
| Aoyagi, T; Aoyagi, Y; Ichida, T; Nomoto, M; Ohkoshi, S; Osaki, A; Takamura, M; Terada, H; Tsubata, S; Uehara, K | 1 |
| Deng, WW; Gu, HX; Li, D; Li, GQ; Wang, JX; Xu, WZ | 1 |
| Agnelli, F; Caccamo, L; Donato, MF; Gatti, S; Maggi, U; Melada, E; Paone, G; Reggiani, P; Rossi, G | 1 |
| Campbell, MS; Enriquez, AD; Reddy, KR | 1 |
| Dong, MH; Joseph, TA; Saab, S; Tong, MJ | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Toyoda, H | 1 |
| Abiru, S; Nagaoka, S; Yatsuhashi, H | 1 |
| Hachimine, D; Nakahashi, Y; Okazaki, K; Seki, T; Wakamatsu, T | 1 |
| Busuttil, RW; Cameron, AM; Ghobrial, RM; Hiatt, JR; Tong, MJ; Zimmerman, MA | 1 |
| Chow, DH; Fung, J; Lai, CL; Ngai, VW; Seto, WK; Tsui, K; Wong, BC; Wong, DK; Yuen, JC; Yuen, MF | 1 |
| Hann, HW | 1 |
| Brechot, C; Castaing, D; Dussaix, E; Fallot, G; Faria, LC; Ferrari, TC; Gigou, M; Guettier, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M | 1 |
| Cattral, MS; Greig, PD; Hemming, AW; Levy, G; Lilly, LB; Philosophe, B; Superina, RA | 1 |
| Melegari, M; Scaglioni, PP; Wands, JR | 1 |
| Omata, M | 1 |
| Main, J; McCarron, B; Thomas, HC | 1 |
| Girardet, JL; Gosselin, G; Imbach, JL; Korba, BE; Périgaud, C | 1 |
| Harrison, TJ; Ling, R | 1 |
| Esquivel, CO; Garcia, G; Imperial, JC; Keeffe, EB; Monge, H; So, SK | 1 |
| Yao, FY | 1 |
| Cheung, ST; Fan, ST; Lo, CM | 1 |
| Chan, PK; Ho, WM; Hui, P; Johnson, PJ; Leung, NW; Steinberg, JL; Tam, JS; Yeo, W; Zee, B; Zhong, S | 1 |
| Cheng, YC; Fu, L | 1 |
| Cahlin, C; Friman, S; Olausson, M | 1 |
| Tanikawa, K | 1 |
| Cai, C; Chen, G; He, X; Huang, J; Lu, M; Wang, G; Yang, Y; Zhu, X | 1 |
| Bock, CT; Klempnauer, J; Locarnini, S; Manns, MP; Tillmann, HL; Torresi, J; Trautwein, C | 1 |
| Fukuda, Y; Hayashi, K; Nakano, I; Takamatsu, J; Toyoda, H | 1 |
| Cheng, YC; Doong, SL; Liotta, DC; Schinazi, RF; Tsai, CH | 1 |
36 review(s) available for lamivudine and Liver Neoplasms
| Article | Year |
|---|---|
Hepatitis Delta: Prevalence, Natural History, and Treatment Options.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Global Health; Hepatitis D; Hepatitis delta Antigens; Hepatitis Delta Virus; Humans; Interferon alpha-2; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Organophosphonates; Prevalence; Risk; RNA, Viral; Serologic Tests | 2020 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Retrospective Studies; Survival Analysis; Telbivudine; Tenofovir; Thymidine | 2017 |
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Tenofovir | 2014 |
What physicians should know about the management of chronic hepatitis B in children: East side story.
Topics: Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Child; Child, Preschool; Diagnostic Errors; Drug Resistance, Viral; Education, Medical, Continuing; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Pediatrics; Treatment Outcome | 2014 |
Postoperative therapy options for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Hepatitis B; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Liver Neoplasms; Neoplasm Recurrence, Local; Postoperative Care; Radiotherapy, Adjuvant; Survival Rate | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic; Guanine; Hepatitis B, Chronic; Humans; Immune Tolerance; Incidence; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Risk; Tenofovir | 2014 |
Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; Drug Resistance, Viral; Female; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 2014 |
Monotherapy for hepatitis B infection: a review of treatment options.
Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Organophosphonates; Telbivudine; Thymidine; Treatment Outcome | 2015 |
Management of chronic hepatitis B infection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Immunization Programs; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Viral Load | 2015 |
The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Topics: Adult; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Interferons; Lamivudine; Liver Neoplasms; Male; Middle Aged; Nucleosides; Nucleotides; Randomized Controlled Trials as Topic; Risk Factors | 2016 |
[Adjuvant therapy after treatment of hepatocellular carcinoma].
Topics: Amino Acids, Branched-Chain; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Immunotherapy, Adoptive; Interferons; Lamivudine; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Obesity; Randomized Controlled Trials as Topic; Risk Factors; Tretinoin; Vitamin K | 2008 |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Thymidine; Treatment Outcome; Virus Replication | 2008 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment.
Topics: Alanine Transaminase; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Reverse Transcriptase Inhibitors; Risk Assessment; Viral Load | 2009 |
Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Topics: Adolescent; Adult; Antiviral Agents; Asia; Carcinoma, Hepatocellular; Child; Child, Preschool; Disease Progression; DNA, Viral; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunization Programs; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cytosine; Female; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Nucleosides; Risk Factors | 2010 |
[Hepatitis B virus (HBV) infection and hepatocarcinogenesis].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Epigenesis, Genetic; Hepatitis B; Hepatitis B Surface Antigens; Humans; Interferons; Lamivudine; Liver Neoplasms; Oncogenes; Population Surveillance; Primary Prevention; Protein Precursors; Secondary Prevention; Trans-Activators; Viral Regulatory and Accessory Proteins | 2010 |
[Rapid progression of hepatocellular carcinoma after surgery: apropos of a case and review of the literature].
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Doxorubicin; Fatal Outcome; Hepatectomy; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Magnetic Resonance Imaging; Male; Ultrasonography; Viral Load | 2010 |
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates | 2011 |
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Postoperative Care | 2011 |
Management of chronic hepatitis B virus infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers.
Topics: Adenine; Adolescent; Adult; Algorithms; Antiviral Agents; Australia; Carcinoma, Hepatocellular; Child; Child, Preschool; Clinical Protocols; Endemic Diseases; Female; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; Interferon-alpha; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Native Hawaiian or Other Pacific Islander; Organophosphonates; Primary Health Care; Rural Health Services | 2003 |
Management of patients with decompensated HBV cirrhosis.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance; Hepatitis B; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Organophosphonates; Prognosis; Reverse Transcriptase Inhibitors; Risk Factors | 2003 |
[Drug therapy of hepatitis B and C].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2003 |
Hepatitis B.
Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Hepatitis B; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Patient Selection; Recombinant Proteins; Reverse Transcriptase Inhibitors; Risk Factors; Sexually Transmitted Diseases; Substance Abuse, Intravenous; United States; Vaccination | 2004 |
Hepatitis B virus infection--natural history and clinical consequences.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Viremia; Virus Replication | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
[Long-term history of chronic hepatitis B virus infection in children].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Genotype; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Neoplasms; Mutation; Risk; Seroepidemiologic Studies | 2004 |
[Current status of treatment for HBV-related cirrhosis].
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Interferon-alpha; Interferon-beta; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Risk; Treatment Outcome | 2004 |
Prevention of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoprevention; Disease Progression; Disease Susceptibility; Hepatitis B; Humans; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Reverse Transcriptase Inhibitors; Secondary Prevention; Vaccination | 2005 |
Therapeutic implications of hepatitis B virus genotypes.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genes, Viral; Genotype; Hepatitis B; Hepatitis B virus; Humans; Interferon-alpha; Lamivudine; Liver Neoplasms | 2005 |
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Neoplasms; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors | 2006 |
[Natural course and recommendation of therapy for HBV infection].
Topics: Antiviral Agents; Biomarkers; Carrier State; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Risk Factors | 2007 |
Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Neoplasms; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2008 |
Treatment of chronic viral hepatitis.
Topics: 2-Aminopurine; Animals; Antimetabolites; Antiviral Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Drug Therapy, Combination; Ducks; Famciclovir; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Animal; Humans; Immunologic Factors; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Marmota; Poultry Diseases; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured | 1998 |
[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].
Topics: Anti-HIV Agents; Antibiosis; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Flaviviridae Infections; GB virus C; Hemophilia A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; HIV-1; Humans; Interferons; Lamivudine; Liver Neoplasms; Liver Transplantation; Prognosis; Ribavirin | 2002 |
13 trial(s) available for lamivudine and Liver Neoplasms
| Article | Year |
|---|---|
Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Splenomegaly; Thrombocytopenia; Viral Load | 2019 |
Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Hepatic Artery; Hepatitis B virus; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Survival Rate; Treatment Outcome; Virus Replication | 2014 |
Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; Virus Activation | 2014 |
Long-term lamivudine therapy in chronic hepatitis B.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Treatment Outcome; Young Adult | 2016 |
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece c
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors | 2011 |
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Japan; Lamivudine; Liver Neoplasms; Male; Middle Aged; Risk Factors; Treatment Outcome; Viral Load | 2012 |
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Drug Resistance; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Severity of Illness Index | 2004 |
[Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B].
Topics: Adult; Aged; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis B; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Reverse Transcriptase Inhibitors; Survival Rate; Thymalfasin; Thymosin | 2005 |
Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 2005 |
Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Pregnancy; Reverse Transcriptase Inhibitors; Risk Factors | 2005 |
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Secondary Prevention; Treatment Outcome; Viral Load; Virus Activation | 2006 |
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Topics: Adult; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2007 |
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, Viral; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Immunohistochemistry; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Risk Assessment; Risk Factors; Secondary Prevention; Sequence Analysis, DNA; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2008 |
126 other study(ies) available for lamivudine and Liver Neoplasms
| Article | Year |
|---|---|
Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Hepatitis B virus; HL-60 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Molecular Structure; Nucleic Acid Synthesis Inhibitors; Time Factors; Transfection; Virus Replication | 2007 |
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.
Topics: Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Conserved Sequence; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Hepatitis B virus; Humans; In Vitro Techniques; Lamivudine; Liver Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Structure, Secondary; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Virus Replication | 2007 |
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Viral; Hepatitis B virus; Humans; Liver Neoplasms; Quinazolinones; Virus Replication | 2020 |
Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Topics: Aldo-Keto Reductase Family 1 member B10; Aldo-Keto Reductases; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Tenofovir | 2023 |
Effects of lamivudine on cell proliferation of liver cancer and expressions of HBsAg, HBeAg, and MMP-9 in patients.
Topics: Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Matrix Metalloproteinase 9; Time Factors; Virus Replication | 2019 |
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Sustained Virologic Response; Tenofovir | 2020 |
Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression.
Topics: Antiviral Agents; DNA, Circular; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Mutation; Trans-Activators; Viral Regulatory and Accessory Proteins; Virus Replication | 2020 |
Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Treatment Outcome | 2021 |
Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; DNA, Viral; Elasticity Imaging Techniques; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Severity of Illness Index | 2017 |
High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Topics: Adult; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Early Detection of Cancer; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Retrospective Studies; Risk Factors; Telbivudine | 2019 |
Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; China; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine | 2019 |
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Middle Aged; Nucleosides; Organophosphonates; Prognosis | 2019 |
Hepatitis B therapy, hepatocellular carcinoma and HBsAg mutants.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Humans; Immunohistochemistry; Lamivudine; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Real-Time Polymerase Chain Reaction; Tomography, X-Ray Computed | 2013 |
HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; DNA, Viral; End Stage Liver Disease; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Secondary Prevention; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.
Topics: Adult; Allografts; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Viral; Female; Graft Rejection; Graft Survival; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Kidney Transplantation; Lamivudine; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Taiwan; Time Factors; Transplant Recipients; Treatment Outcome; Virus Activation | 2014 |
[Clinical observation of YMDD mutation in HBV-related primary liver cancer with lamivudine].
Topics: Adult; DNA, Viral; Female; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Point Mutation; Retrospective Studies | 2013 |
Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.
Topics: Adult; Age Factors; Antiviral Agents; Aspartic Acid; Carcinoma, Hepatocellular; China; DNA, Viral; Drug Therapy, Combination; End Stage Liver Disease; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Methionine; Middle Aged; Mutation; Retrospective Studies; Risk Factors; Secondary Prevention; Sex Factors; Tyrosine | 2014 |
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2013 |
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Time Factors | 2014 |
Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Telbivudine; Thymidine; Time Factors; Treatment Outcome | 2014 |
Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunohistochemistry; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Phosphorylation; Protein Isoforms; Signal Transduction; Smad3 Protein; Telbivudine; Thymidine; Treatment Outcome; Young Adult | 2014 |
[Loss of hbs antigen after treatment with analogues: infrequent but stable and beneficial].
Topics: Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Prognosis; Republic of Korea; Treatment Outcome | 2013 |
Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2014 |
Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Topics: Adult; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Kaplan-Meier Estimate; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Patient Acuity; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time | 2014 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Hungary; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2014 |
Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Arabinofuranosyluracil; Biomarkers; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Time Factors | 2014 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2014 |
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Greece; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Risk Assessment; Treatment Outcome | 2015 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir; Thymidine | 2014 |
Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Disease-Free Survival; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Young Adult | 2014 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma.
Topics: Adult; Angiography; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hepatectomy; Hepatic Artery; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Postoperative Period | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Turkey | 2016 |
Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Drug Administration Schedule; Drug Resistance, Viral; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Propensity Score; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
Topics: Age Factors; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2016 |
Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Recurrence; Remission Induction; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2016 |
Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; DNA, Circular; Drug Resistance, Viral; Fatty Liver; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Lamivudine; Liver; Liver Neoplasms; Male; Middle Aged; Necrosis; Organophosphonates; Protein Precursors; Sequence Deletion; Viral Load; Young Adult | 2016 |
Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals.
Topics: Adult; Antiviral Agents; Ascites; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Prothrombin Time; Retrospective Studies; Serum Albumin | 2016 |
Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Risk Factors; Treatment Outcome | 2016 |
Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Phosphorous Acids; Platelet Count; Proportional Hazards Models; Risk Factors; ROC Curve; Time Factors | 2017 |
Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Propensity Score; Retrospective Studies; Treatment Outcome | 2016 |
Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Recurrence; Tacrolimus; Tissue Donors; Treatment Outcome | 2016 |
Comparative Effectiveness of Lamivudine versus Entecavir in Patients with Hepatocellular Carcinoma: Watch out for Confounders!
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Treatment Outcome | 2016 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepatocellular; Culture Media, Conditioned; DNA, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HT29 Cells; Humans; Interferons; Interleukins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Polymorphism, Genetic; Recombinant Proteins; Tenofovir; Up-Regulation; Young Adult | 2018 |
New diagnostic tools of hepatitis virus-related liver diseases. Preface.
Topics: Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diagnosis, Differential; Drug Resistance, Viral; Elasticity Imaging Techniques; Ferric Compounds; Hepatitis B virus; Hepatitis, Viral, Human; Humans; Iron; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Oxides; Tomography, X-Ray Computed | 2008 |
The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Topics: Adult; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; NIH 3T3 Cells; Taiwan; Transcriptional Activation | 2008 |
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Lamivudine; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Treatment Outcome | 2008 |
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates | 2009 |
Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.
Topics: Adult; Animals; Carcinoma, Hepatocellular; Codon, Nonsense; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Transplantation; NIH 3T3 Cells; Reverse Transcriptase Inhibitors; Viral Envelope Proteins | 2009 |
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Retrospective Studies; Treatment Outcome | 2009 |
The management of cirrhotic ascites.
Topics: Antiviral Agents; Ascites; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Liver Transplantation; Practice Guidelines as Topic | 2009 |
Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Case-Control Studies; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation; Retrospective Studies; Risk Assessment; Time Factors; Young Adult | 2010 |
Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoprevention; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Nucleotides; Polyethylene Glycols; Recombinant Proteins | 2010 |
Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoprevention; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Nucleosides; Nucleotides; Polyethylene Glycols; Primary Prevention; Recombinant Proteins; Selection Bias; Tertiary Prevention | 2010 |
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Disease-Free Survival; Female; Guanine; Hepatectomy; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organophosphonates; Proportional Hazards Models; Risk Assessment; Risk Factors; RNA, Viral; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Accelerated progression of hepatocellular carcinoma with cytokeratin 19 expression during treatment with lamivudine for hepatitis B virus-related liver cirrhosis.
Topics: Carcinoma, Hepatocellular; Disease Progression; Fatal Outcome; Hepatitis B virus; Humans; Keratin-19; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged | 2011 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male | 2011 |
[New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2011 |
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Guanine; Hepatectomy; Hepatitis B, Chronic; Humans; Lamivudine; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2011 |
Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Base Sequence; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Nucleic Acid Amplification Techniques; Retrospective Studies; Risk Factors | 2011 |
Can tertiary prevention of hepatocellular carcinoma be achieved by nucleos(t)ide analogs therapy of hepatitis B?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Guanine; Hepatectomy; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male | 2011 |
Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; DNA, Viral; Drug Costs; Drug Resistance, Viral; Guanine; Health Care Costs; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Hospitals, Public; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Quality-Adjusted Life Years; Viral Load | 2012 |
How does hepatitis B virus infection react to hepatocellular carcinoma treatment?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Virus Activation | 2012 |
Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Disease-Free Survival; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nucleosides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Retrospective Studies; Severity of Illness Index | 2012 |
Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Topics: Administration, Oral; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nucleotides; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2012 |
Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers.
Topics: Biomarkers; Hepatitis B; Hepatitis B e Antigens; Humans; Immunologic Factors; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2012 |
Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis.
Topics: Aged; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Reverse Transcriptase Inhibitors | 2012 |
Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Guanine; Hepatitis B Core Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Proportional Hazards Models | 2013 |
Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Recurrence; Time Factors; Treatment Outcome; Viral Load | 2013 |
Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Viral; Female; Fluorescence Polarization; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Mutation, Missense; Nucleic Acid Hybridization; Virology | 2013 |
A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mutation, Missense | 2012 |
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Topics: Adult; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2013 |
Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organophosphonates; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Viral Load | 2013 |
Recent progress and new trends in the treatment of hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms | 2002 |
Advances in liver disease. Highlights from the 51st Annual Meeting of the American Association for the Study of Liver Diseases, October 27-31, 2000, Dallas, TX.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins | 2001 |
Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Cytidine Triphosphate; Dioxolanes; DNA Replication; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Gene Expression Regulation, Viral; Guanosine; Hepadnaviridae Infections; Hepatitis B virus; Hepatitis B Virus, Duck; Hepatitis, Viral, Animal; Hepatocytes; Humans; Lamivudine; Liver Neoplasms; Mutation; Purine Nucleosides; Reverse Transcriptase Inhibitors; Thiophenes; Tumor Cells, Cultured | 2002 |
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Topics: Adenine; Baculoviridae; Carcinoma, Hepatocellular; Drug Resistance, Viral; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; In Vitro Techniques; Lamivudine; Liver Neoplasms; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured; Virus Replication | 2003 |
Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus-positive donor.
Topics: Adult; Antiviral Agents; Cadaver; Carcinoma, Hepatocellular; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Tissue Donors | 2003 |
[Genotyping of hepatitis B virus and clinical investigation].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Treatment Outcome | 2002 |
Decompensated hepatitis B virus-related cirrhosis successfully treated with lamivudine allowing surgery for hepatocellular carcinoma.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatitis B; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Radiography | 2003 |
Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2.
Topics: Anti-HIV Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Green Fluorescent Proteins; Hepatitis B, Chronic; Humans; Immunohistochemistry; Interferons; Isoenzymes; Lamivudine; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Plasmids; Prostaglandin-Endoperoxide Synthases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins | 2004 |
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Evaluation; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome | 2004 |
Prevention of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Mutation; Virus Replication | 2004 |
Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chi-Square Distribution; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Treatment Outcome | 2004 |
[Inhibition of transcription and expression of X gene by lamivudine].
Topics: Carcinoma, Hepatocellular; Female; Gene Expression Regulation, Neoplastic; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Male; Reverse Transcriptase Inhibitors; Trans-Activators; Transcription, Genetic; Viral Regulatory and Accessory Proteins | 2005 |
Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome | 2005 |
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Failure; Liver Neoplasms; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tomography, X-Ray Computed; Ultrasonography; Virus Replication | 2005 |
[Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2].
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Lamivudine; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Octreotide; Proliferating Cell Nuclear Antigen; Receptors, Somatostatin; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins | 2005 |
[Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
Topics: Administration, Oral; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Hepatitis B, Chronic; Humans; Immunization, Passive; Immunoglobulin G; Injections, Intramuscular; Lamivudine; Liver Failure; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Secondary Prevention | 2005 |
Liver transplantation for patients with hepatitis B virus-related diseases.
Topics: Antiviral Agents; Combined Modality Therapy; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Failure, Acute; Liver Neoplasms; Liver Transplantation; Male; Secondary Prevention; Survival Rate | 2001 |
Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.
Topics: Antiviral Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Conserved Sequence; Genetic Vectors; Genome, Viral; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Molecular Sequence Data; Polymerase Chain Reaction; Reproducibility of Results; Restriction Mapping; RNA, Messenger; RNA, Small Interfering; RNA, Viral; Transfection | 2005 |
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Resistance, Viral; Ducks; Filaggrin Proteins; Hepatitis B virus; Hepatitis B Virus, Duck; Hepatocytes; Humans; Lamivudine; Liver Neoplasms; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Virus Replication | 2006 |
Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carcinoma, Small Cell; Fatal Outcome; HIV Seropositivity; Humans; Lamivudine; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Ritonavir; Saquinavir; Zidovudine | 2006 |
Prevention of mortality from hepatitis B and hepatitis C.
Topics: Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Liver Cirrhosis; Liver Neoplasms | 2006 |
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
Topics: Adult; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C Antibodies; HIV Infections; Humans; Lamivudine; Liver Neoplasms; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Survival Analysis | 2006 |
Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Famciclovir; Female; Heart Transplantation; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Liver Neoplasms; Male; Middle Aged | 2006 |
Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Retrospective Studies; Risk Factors | 2007 |
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resistance, Viral; Follow-Up Studies; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Lamivudine; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2007 |
Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Replication; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; RNA, Messenger; RNA, Small Interfering; RNA, Viral; Transfection; Virus Replication | 2007 |
Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection.
Topics: Adult; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Hepatitis D; Humans; Immunoglobulins; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Reoperation; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis | 2007 |
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Interferon-beta; Japan; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2007 |
Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; DNA, Viral; Female; Hepatitis B virus; Humans; Lamivudine; Life Expectancy; Liver Cirrhosis; Liver Neoplasms; Male; Models, Theoretical; Reverse Transcriptase Inhibitors; Risk Factors | 2007 |
Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Doxorubicin; Health Care Costs; Hepatitis B; Humans; Lamivudine; Liver Neoplasms; Lymphoma; Prednisolone; Treatment Outcome; Vincristine | 2007 |
Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; DNA, Viral; Female; Follow-Up Studies; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Japan; Kaplan-Meier Estimate; Lamivudine; Liver Neoplasms; Male; Middle Aged; Mutation; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2007 |
The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glycyrrhizic Acid; Humans; Lamivudine; Liver Neoplasms; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B.
Topics: Analysis of Variance; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Liver Neoplasms; Neoplasm Staging; Postoperative Complications; Recurrence; Retrospective Studies; Survival Analysis; Survivors; Time Factors; Virus Diseases | 2007 |
The University of Toronto liver transplant program.
Topics: Adult; Alprostadil; Antiviral Agents; Child; Graft Survival; Hepatitis B; Hepatitis C; Hospitals, University; Humans; Immunization, Passive; Immunoglobulins; Immunosuppression Therapy; Lamivudine; Liver Neoplasms; Liver Transplantation; Ontario; Patient Selection; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Transplantation, Heterologous | 1996 |
Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Blotting, Northern; Carcinoma, Hepatocellular; Cell Line; Famciclovir; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Hydroxyurea; Lamivudine; Liver Neoplasms; Molecular Sequence Data; Mutation; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; Transfection; Tumor Cells, Cultured; Virus Replication | 1998 |
Treatment of chronic hepatitis B infection.
Topics: Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Reverse Transcriptase Inhibitors | 1998 |
The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir.
Topics: Acyclovir; Antiviral Agents; Drug Evaluation, Preclinical; Drug Synergism; Hepatitis B virus; Hepatoblastoma; Humans; Lamivudine; Liver Neoplasms; Microbial Sensitivity Tests; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured | 1999 |
Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Base Sequence; Blotting, Southern; DNA Replication; DNA, Circular; DNA, Viral; Drug Resistance, Microbial; Genes, Viral; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1999 |
Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?
Topics: Adolescent; Adult; Asian People; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B e Antigens; Humans; Immunization, Passive; Immunoglobulins; Immunosuppression Therapy; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Methylprednisolone; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors; Survival Rate | 1999 |
Elevated alpha-fetoprotein levels in hepatocellular carcinoma.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Anti-HIV Agents; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carcinoma, Hepatocellular; Diagnosis, Differential; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male | 1999 |
Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma.
Topics: Antiviral Agents; Asia; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lamivudine; Liver Neoplasms; Liver Transplantation; Recurrence | 2000 |
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
Topics: Adult; Age Factors; Alanine Transaminase; Female; Hepatitis Antibodies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Immunosuppressive Agents; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies; Risk Factors; Sex Factors; Virus Activation | 2000 |
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Topics: Acyclovir; Antigens, Viral; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Microbial; Guanine; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Microbial Sensitivity Tests; Time Factors; Transfection; Tumor Cells, Cultured; Virus Replication | 2000 |
Orthotopic liver transplantation in patients with hepatitis B-related liver disease.
Topics: Adolescent; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Follow-Up Studies; Graft Rejection; Hepatitis B; Humans; Lamivudine; Liver Neoplasms; Liver Transplantation; Middle Aged; Postoperative Complications; Retrospective Studies; Survival Rate; Time Factors | 2001 |
Much remains to be solved in lamivudine treatment for HBV-associated liver diseases.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis Viruses; Humans; Lamivudine; Liver Neoplasms; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Prevention and treatment of hepatitis B relapse after liver transplantation.
Topics: Adult; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence | 2001 |
Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
Topics: Amino Acid Sequence; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Neoplasms; Liver Transplantation; Molecular Sequence Data; Reverse Transcriptase Inhibitors; RNA, Messenger; RNA, Viral; Transfection; Tumor Cells, Cultured; Virus Replication | 2002 |
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.
Topics: Antiviral Agents; Blotting, Northern; Carcinoma, Hepatocellular; Cell Survival; DNA, Mitochondrial; Hepatitis B virus; Humans; In Vitro Techniques; Lamivudine; Liver Neoplasms; Mitochondria; Molecular Structure; RNA, Viral; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication; Zalcitabine | 1991 |